AbbVie Lowers 2024 Profit Forecast Amid $1.6B Acquisition Expenses
AbbVie reduces its 2024 profit outlook due to $1.6 billion in acquisition-related costs, impacting adjusted earnings. Discover the financial implications.
Topic
AbbVie
A collection of 4 issues
AbbVie Revises 2024 Profit Outlook Amid Acquisition Costs
AbbVie lowers its 2024 profit forecast due to acquisition expenses, impacting expected earnings per share. Discover the financial implications and future outlook.
AbbVie Expands Portfolio with $20B Acquisitions
AbbVie enhances its drug development pipeline by acquiring Cerevel Therapeutics, ImmunoGen, and Aliada, investing over $20 billion in neuroscience and cancer therapies.
AbbVie Cuts 2024 Profit Forecast Amid Acquisition Costs
AbbVie revises its 2024 profit outlook, citing $1.6 billion in acquisition-related expenses from milestone payments and R&D costs.